大洋生物
(003017)
| 流通市值：11.17亿 | | | 总市值：13.84亿 |
| 流通股本：6776.36万 | | | 总股本：8400.00万 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 468,492,052.31 | 345,834,642.63 | 96,847,409.95 | 131,111,370.93 |
| 应收票据及应收账款 | 75,036,536.05 | 62,099,739.59 | 77,666,923.33 | 70,185,207.76 |
| 其中：应收票据 | 1,556,480.15 | 3,234,292.34 | 770,000 | 1,194,625 |
| 应收账款 | 73,480,055.9 | 58,865,447.25 | 76,896,923.33 | 68,990,582.76 |
| 应收款项融资 | 54,936,070.15 | 92,428,770.39 | 90,225,241.14 | 68,776,621.42 |
| 预付款项 | 16,382,584.87 | 12,087,492.92 | 25,556,115.84 | 24,861,798.86 |
| 其他应收款合计 | 2,425,143.17 | 2,264,496.54 | 2,799,058.46 | 2,037,837.77 |
| 存货 | 127,408,378.73 | 127,830,386.92 | 138,843,313.02 | 126,871,327.15 |
| 其他流动资产 | 6,731,012.24 | 6,176,038.51 | 6,397,424.94 | 7,841,150.55 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 751,411,777.52 | 784,646,819.56 | 756,131,103.2 | 728,163,051.42 |
| 非流动资产: | | | | |
| 长期股权投资 | 17,762,640.62 | 8,923,925.25 | 9,000,893.39 | 2,500,893.39 |
| 其他非流动金融资产 | 19,393,052 | - | - | - |
| 投资性房地产 | 372,332 | 261,688.72 | 283,120.12 | 304,551.52 |
| 固定资产 | 518,702,627.63 | 532,404,248.41 | 547,477,028.33 | 563,661,841.66 |
| 在建工程 | 122,025,350.26 | 97,116,162.31 | 61,002,088.87 | 52,147,353.8 |
| 使用权资产 | 1,452,378.88 | 1,670,235.73 | 143,017.13 | 357,542.75 |
| 无形资产 | 93,299,489.18 | 94,504,860.97 | 94,771,709.78 | 95,364,217.9 |
| 长期待摊费用 | 12,732.26 | 25,468.4 | 38,204.54 | 50,940.68 |
| 递延所得税资产 | 43,736,367.24 | 44,425,566.14 | 42,133,614.2 | 45,371,476.87 |
| 其他非流动资产 | 23,263,135.94 | 21,699,718.36 | 21,507,718.05 | 20,052,050.77 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 840,020,106.01 | 801,031,874.29 | 776,357,394.41 | 779,810,869.34 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,591,431,883.53 | 1,585,678,693.85 | 1,532,488,497.61 | 1,507,973,920.76 |
| 流动负债: | | | | |
| 短期借款 | 277,827,056 | 316,257,903.56 | 295,320,000 | 252,114,104.19 |
| 交易性金融负债 | - | 331,366.2 | - | 60 |
| 应付票据及应付账款 | 127,458,261.68 | 123,235,252.74 | 99,138,049.28 | 125,774,290.75 |
| 其中：应付票据 | 42,267,994.8 | 48,280,674.98 | 44,725,260.49 | 20,320,105.94 |
| 应付账款 | 85,190,266.88 | 74,954,577.76 | 54,412,788.79 | 105,454,184.81 |
| 合同负债 | 4,596,833.81 | 6,970,714.75 | 9,273,641.6 | 8,031,182.85 |
| 应付职工薪酬 | 9,591,918.47 | 9,240,658.09 | 13,555,814.19 | 13,866,494.53 |
| 应交税费 | 3,199,693.59 | 2,459,346.28 | 4,662,450.91 | 15,000,536.83 |
| 其他应付款合计 | 55,014,101.97 | 31,247,199.84 | 31,310,037.51 | 31,421,051.91 |
| 其中:应付利息 | 59,979.17 | - | - | - |
| 应付股利 | 24,000,000 | - | - | - |
| 一年内到期的非流动负债 | - | - | 30,028,875 | 30,028,875 |
| 其他流动负债 | 1,571,324.68 | 3,152,788.77 | 1,059,478.9 | 2,002,124.32 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 479,259,190.2 | 492,895,230.23 | 484,348,347.39 | 478,238,720.38 |
| 非流动负债: | | | | |
| 长期借款 | 69,000,000 | 42,018,375 | - | - |
| 租赁负债 | 1,293,662.68 | 1,297,932.61 | - | - |
| 递延收益 | 10,891,995.28 | 11,467,855.84 | 11,404,618.53 | 11,961,376.98 |
| 递延所得税负债 | 29,656,429.23 | 30,579,575.64 | 31,560,717.33 | 32,724,395.41 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 110,842,087.19 | 85,363,739.09 | 42,965,335.86 | 44,685,772.39 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 590,101,277.39 | 578,258,969.32 | 527,313,683.25 | 522,924,492.77 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 60,000,000 | 60,000,000 | 60,000,000 | 60,000,000 |
| 资本公积 | 546,951,229.89 | 545,970,103.49 | 537,189,324.19 | 537,189,324.19 |
| 减:库存股 | 25,250,400 | 25,250,400 | 25,418,400 | 25,418,400 |
| 专项储备 | 2,169,183.26 | 1,558,349.52 | 890,546.63 | 162,142.5 |
| 盈余公积 | 30,000,000 | 30,000,000 | 30,000,000 | 30,000,000 |
| 未分配利润 | 387,460,592.99 | 395,141,671.52 | 402,513,343.54 | 383,116,361.3 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,001,330,606.14 | 1,007,419,724.53 | 1,005,174,814.36 | 985,049,427.99 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,001,330,606.14 | 1,007,419,724.53 | 1,005,174,814.36 | 985,049,427.99 |
| 负债和股东权益合计 | 1,591,431,883.53 | 1,585,678,693.85 | 1,532,488,497.61 | 1,507,973,920.76 |
| 公告日期 | 2023-10-24 | 2023-08-30 | 2023-04-25 | 2023-04-25 |
| 审计意见(境内) | | 标准无保留意见 | | 标准无保留意见 |